Recruiting Advanced Solid Tumors Studies in Harbin
Study of SGN1 in Patients With Advanced Solid Tumor
Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Ration...
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions...
About Advanced Solid Tumors Clinical Trials in Harbin
Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.
There are currently 2 advanced solid tumors clinical trials recruiting participants in Harbin, HEILONGJIANG. These studies are seeking a combined 130 participants. Research is being sponsored by Guangzhou Sinogen Pharmaceutical Co., Ltd, Teligene US. Clinical trial participation is free and participants receive study-related medical care at no cost.
Advanced Solid Tumors Clinical Trials in Harbin — FAQ
Are there advanced solid tumors clinical trials in Harbin?
Yes, there are 2 advanced solid tumors clinical trials currently recruiting in Harbin, HEILONGJIANG. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Harbin?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Harbin research site will contact you about next steps.
Are clinical trials in Harbin free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Harbin studies also compensate for your time and travel.
What advanced solid tumors treatments are being tested?
The 2 active trials in Harbin are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.
Data updated March 2, 2026 from ClinicalTrials.gov